Full-Time

Head of Commercial

Pattern Bioscience

Pattern Bioscience

51-200 employees

AI-driven rapid bacterial ID and AST

No salary listed

Austin, TX, USA

Hybrid

Onsite in Austin, TX preferred; hybrid or remote options available with travel.

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
Marketing
Customer Service
Data Analysis
Requirements
  • Bachelor’s degree in Science, Biomedical, Business or related field
  • Minimum of 15 years of experience in commercial roles in diagnostics, medtech, life sciences
  • Demonstrated success building and scaling commercial functions in early-stage or high-growth environment and achieving revenue goals
  • Experience operating in startup or venture-backed environments with limited infrastructure and evolving strategy
Responsibilities
  • Develop and execute the Go-to-Market plan for Pattern’s Pneumonia ID/AST solution
  • Build and manage Sales, Marketing, Customer Service & Support teams and work cross-functionally with all other departments to ensure effective commercial execution
  • Own revenue generation and leverage best-practices in creating and managing performance metrics, funnel development, forecasting and clinical implementation
  • Develop tailored value messaging to key stakeholders in hospitals leveraging workflow, clinical and health-economic value to drive hospital adoption
  • Lead engagement and negotiation with major IDNs and GPOs and C-suite to secure system-wide approval and master agreements
  • Track customer satisfaction, engagement, and product quality and leverage data to drive ongoing product improvement aligned with driving revenue and profitability
  • Lead pricing, reimbursement, KOL engagement, guidelines and health-economic education to drive customer demand for Pattern’s solutions
  • Own company strategy and product roadmap to drive revenue growth and company value creation
  • Develop and own commercial expansion via alternate channels outside the US
  • Work closely with regulatory and medical affairs on evidence generation tailored to driving revenue growth and market expansion
  • Own the commercial budget and contribute to both annual and long-range revenue and budget planning
Desired Qualifications
  • MBA or advanced technical degree (MS, PhD) strongly preferred
  • Experience in infectious disease diagnostics and launching new, innovative products highly preferred
  • Experience operating in and comfort with pre-revenue startups is a plus
  • Thorough knowledge of US Hospital Diagnostic Lab customer profile and purchasing process with experience selling to integrated delivery networks and working with group purchasing organizations
  • Experience launching products that require behavior change and clinical pathway integration is a plus
  • Experience operating in startup or venture-backed environments with limited infrastructure and evolving strategy

Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.

Company Size

51-200

Company Stage

Series D

Total Funding

$91.6M

Headquarters

Austin, Texas

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
  • $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
  • Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.

What critics are saying

  • Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
  • BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
  • Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.

What makes Pattern Bioscience unique

  • Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
  • Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
  • Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pattern Bioscience who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

-1%
Legal Desire
Nov 19th, 2025
Pattern Bioscience Raises $43M Series D

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.

VCBay
Apr 29th, 2023
Austin-based Biotech startup Pattern Bioscience raises USD 28.7 million in Series C funding

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.

Business Wire
Apr 28th, 2023
Pattern Bioscience Secures $28.7 Million in Series C Financing

Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform

FinSMEs
Apr 27th, 2023
Pattern Bioscience Raises $28.7M in Series C Financing

Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.

360Dx
Apr 27th, 2023
Pattern Bioscience Closes $28.7M Series C Financing Round | 360Dx

Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.